Abstract
The seeding of amyloid-β 40 (Aβ40) oligomers from monomers is the initial step of Aβ aggregation, and many reports have suggested that cholesterol enhances this step. We studied the potential of secosteroid vitamin D derivatives for Aβ40 aggregation in vitro. The quartz-crystal microbalance technique demonstrated that vitamin D3 does not show any effect on Aβ40 aggregation while vitamin D2 promoted it and docking simulation but that vitamin D2 has high potential in this regard. Thus, stacking of the Phe19 benzene ring in Aβ40 and the C22-C23 double bond in vitamin D2 may alter the energy of these molecules. Electron microscopy revealed the potential of vitamin D2 to increase Aβ40 aggregation. Thioflavin-T assays indicated that Vitamin D2 induced increased fluorescence at 490 nm, as typically observed for amyloid fibrils but also for protofibrils; in both cases this reflects of the increase of β-sheet contents. Aβ40 aggregation was further confirmed in ELISA, SDS-PAGE and dot blot analysis which revealed changes in protease K resistance. These results suggest a possible mechanism, of how vitamin D2 could increase Aβ40 aggregation and the docking simulation explains, why the same is not observed with vitamin D3.
Keywords: Aggregation, Alzheimer's disease, amyloid-β, β-sheet formation, quartz-crystal microbalance technique, vitamin D derivatives.
Current Alzheimer Research
Title:Different Effect of Vitamin D2 and Vitamin D3 on Amyloid-β40 Aggregation In Vitro
Volume: 11 Issue: 8
Author(s): Midori Suenaga, Hironobu Takahashi, Hiroshi Imagawa, Michiru Wagatsuma, Shinji Ouma, Yoshio Tsuboi, Akiko Furuta and Yoichi Matsunaga
Affiliation:
Keywords: Aggregation, Alzheimer's disease, amyloid-β, β-sheet formation, quartz-crystal microbalance technique, vitamin D derivatives.
Abstract: The seeding of amyloid-β 40 (Aβ40) oligomers from monomers is the initial step of Aβ aggregation, and many reports have suggested that cholesterol enhances this step. We studied the potential of secosteroid vitamin D derivatives for Aβ40 aggregation in vitro. The quartz-crystal microbalance technique demonstrated that vitamin D3 does not show any effect on Aβ40 aggregation while vitamin D2 promoted it and docking simulation but that vitamin D2 has high potential in this regard. Thus, stacking of the Phe19 benzene ring in Aβ40 and the C22-C23 double bond in vitamin D2 may alter the energy of these molecules. Electron microscopy revealed the potential of vitamin D2 to increase Aβ40 aggregation. Thioflavin-T assays indicated that Vitamin D2 induced increased fluorescence at 490 nm, as typically observed for amyloid fibrils but also for protofibrils; in both cases this reflects of the increase of β-sheet contents. Aβ40 aggregation was further confirmed in ELISA, SDS-PAGE and dot blot analysis which revealed changes in protease K resistance. These results suggest a possible mechanism, of how vitamin D2 could increase Aβ40 aggregation and the docking simulation explains, why the same is not observed with vitamin D3.
Export Options
About this article
Cite this article as:
Suenaga Midori, Takahashi Hironobu, Imagawa Hiroshi, Wagatsuma Michiru, Ouma Shinji, Tsuboi Yoshio, Furuta Akiko and Matsunaga Yoichi, Different Effect of Vitamin D2 and Vitamin D3 on Amyloid-β40 Aggregation In Vitro, Current Alzheimer Research 2014; 11 (8) . https://dx.doi.org/10.2174/156720501108140910121139
DOI https://dx.doi.org/10.2174/156720501108140910121139 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Cardiovascular & Hematological Agents in Medicinal Chemistry Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Cellular Therapy for Heart Failure
Current Cardiology Reviews Gene Therapy in Lung Transplantation
Current Gene Therapy Editorial (Thematic Issue):Inflammation and Atherosclerosis: The Role of Novel Biomarkers (Part-I)
Current Medicinal Chemistry Receptor Fragments: Intracellular Signaling and Novel Therapeutic Targets
Current Hypertension Reviews Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
Current Drug Safety Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review
Cardiovascular & Hematological Disorders-Drug Targets Goal Directed Fluid Therapy
Current Pharmaceutical Design Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery Meet Our Editorial Board Member
Current Drug Safety The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Serelaxin: New Investigational Treatment in Acute Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry